



# Toxicological Profile for DDT, DDE, and DDD

Draft for Public Comment

December 2019



U.S. Department of Health and Human Services  
Agency for Toxic Substances and Disease Registry

## **DISCLAIMER**

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

## FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: [www.regulations.gov](http://www.regulations.gov). Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry  
Division of Toxicology and Human Health Sciences  
Environmental Toxicology Branch  
1600 Clifton Road, N.E.  
Mail Stop S102-1  
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breysse, Ph.D., CIH  
Director, National Center for Environmental Health and  
Agency for Toxic Substances and Disease Registry  
Centers for Disease Control and Prevention

## VERSION HISTORY

Date	Description
December 2019	Draft for public comment toxicological profile released
November 2008	Addendum to the toxicological profile released
September 2002	Final toxicological profile released
May 1994	Final toxicological profile released
August 1990	Final toxicological profile released

## CONTRIBUTORS & REVIEWERS

### CHEMICAL MANAGER TEAM

Obaid Faroon, D.V.M., Ph.D. (Lead)  
Patricia Ruiz, Ph.D.  
Dennis Jones, D.V.M., Ph.D.  
Sam Keith, M.S., C.H.P.  
Franco Scinicariello, M.D., M.P.H.

Peter McClure, Ph.D., D.A.B.T.  
Fernando Llados, Ph.D.  
Lisa Ingerman, Ph.D., D.A.B.T.  
Mario Citra, Ph.D.  
Shelley Stevens, Ph.D.

ATSDR, Division of Toxicology and Human Health  
Sciences, Atlanta, GA

SRC, Inc., North Syracuse, NY

### REVIEWERS

#### Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

#### Additional reviews for science and/or policy:

ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice, EPA.

### PEER REVIEWERS

1. George Howell III, Ph.D., Assistant Professor, Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University
2. Charles J. Everett, Ph.D., U.S. Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, South Carolina
3. David O. Carpenter, M.D., Director, Institute for Health and the Environment, A Collaborating Centre of the World Health Organization, University at Albany, Rensselaer, New York

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

## CONTENTS

FOREWORD .....	ii
VERSION HISTORY .....	v
CONTRIBUTORS & REVIEWERS .....	vi
CONTENTS.....	vii
LIST OF FIGURES .....	ix
LIST OF TABLES .....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH. ....	1
1.1 OVERVIEW AND U.S. EXPOSURES .....	1
1.2 SUMMARY OF HEALTH EFFECTS.....	3
1.3 MINIMAL RISK LEVELS (MRLs) .....	5
CHAPTER 2. HEALTH EFFECTS.....	15
2.1 INTRODUCTION.....	15
2.2 DEATH .....	64
2.3 BODY WEIGHT.....	67
2.4 RESPIRATORY.....	73
2.5 CARDIOVASCULAR.....	74
2.6 GASTROINTESTINAL.....	80
2.7 HEMATOLOGICAL .....	80
2.8 MUSCULOSKELETAL .....	83
2.9 HEPATIC.....	85
2.10 RENAL .....	91
2.11 DERMAL .....	93
2.12 OCULAR .....	93
2.13. ENDOCRINE.....	94
2.14. IMMUNOLOGICAL .....	106
2.15 NEUROLOGICAL.....	124
2.16 REPRODUCTIVE .....	150
2.17 DEVELOPMENTAL .....	187
2.18 OTHER NONCANCER.....	210
2.19 CANCER.....	223
2.20 GENOTOXICITY .....	232
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS .....	243
3.1 TOXICOKINETICS.....	243
3.1.1 Absorption .....	243
3.1.2 Distribution .....	244
3.1.3 Metabolism.....	247
3.1.4 Excretion .....	249
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .....	250
3.1.6 Animal-to-Human Extrapolations .....	256
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE... 258	258
3.3 BIOMARKERS OF EXPOSURE AND EFFECT.....	261
3.3.1 Biomarkers of Exposure.....	262
3.3.2 Biomarkers of Effect.....	263
3.4 INTERACTIONS WITH OTHER CHEMICALS .....	263

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION .....	266
4.1 CHEMICAL IDENTITY .....	266
4.2 PHYSICAL AND CHEMICAL PROPERTIES .....	267
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE .....	270
5.1 OVERVIEW .....	270
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	274
5.2.1 Production .....	274
5.2.2 Import/Export.....	275
5.2.3 Use .....	275
5.2.4 Disposal.....	276
5.3 RELEASES TO THE ENVIRONMENT .....	277
5.3.1 Air .....	277
5.3.2 Water.....	278
5.3.3 Soil .....	278
5.4 ENVIRONMENTAL FATE .....	279
5.4.1 Transport and Partitioning.....	279
5.4.2 Transformation and Degradation .....	283
5.5 LEVELS IN THE ENVIRONMENT.....	288
5.5.1 Air .....	289
5.5.2 Water.....	291
5.5.3 Sediment and Soil .....	294
5.5.4 Other Media .....	299
5.6 GENERAL POPULATION EXPOSURE.....	317
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	337
CHAPTER 6. ADEQUACY OF THE DATABASE.....	341
6.1 INFORMATION ON HEALTH EFFECTS.....	341
6.2 IDENTIFICATION OF DATA NEEDS .....	341
6.3 ONGOING STUDIES.....	352
CHAPTER 7. REGULATIONS AND GUIDELINES .....	353
CHAPTER 8. REFERENCES .....	356
APPENDICES	
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS .....	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK.....	B-1
APPENDIX C. USER'S GUIDE .....	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....	D-1
APPENDIX E. GLOSSARY .....	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	F-1



## LIST OF FIGURES

1-1. Health Effects Following Oral Exposure to DDT, DDE, and DDD .....	4
1-2. Summary of Sensitive Targets of DDT, DDE, and DDD – Oral.....	13
2-1. Overview of the Number of Studies Examining DDT, DDE, and DDD Health Effects .....	19
2-2. Levels of Significant Exposure to DDT, DDE, and DDD – Oral.....	56
3-1. Proposed Metabolic Pathway of <i>p,p'</i> -DDT by Rat Liver Microsomes .....	247
3-2. Proposed Metabolic Scheme Converting DDT to DDA, the Principal Metabolite Excreted in Rat Urine .....	248
3-3. Proposed Metabolic Pathway for the Conversion of <i>p,p'</i> -DDE to its Methylsulfone Derivative .....	249
3-4. Diagrammatic Representation of the Physiologically Based Pharmacokinetic Model for Gestation.....	252
3-5. Diagrammatic Representation of the Physiologically Based Pharmacokinetic Model for the Lactating Dam and Nursing Pup .....	253
3-6. Conceptual Representation of the Mother-Infant Physiologically Based Pharmacokinetic Model.....	257
5-1. Number of NPL Sites with DDT, DDE, and DDD Contamination .....	270
5-2. Sum of DDT-like Compounds in $\mu\text{g}/\text{kg}$ Lipid in Pooled Human Samples from Different Countries.....	329
6-1. Summary of Existing Health Effects Studies on DDT, DDE, and DDD By Route and Endpoint .....	342

## LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for DDT, DDE, and DDD .....	14
2-1. Levels of Significant Exposure to DDT, DDE, and DDD – Oral.....	20
2-2. Summary of Studies of Associations between DDT Exposure Biometrics and Body Weight Status .....	68
2-3. Summary of Studies of Associations between DDT Exposure Biometrics and Cardiovascular Endpoints .....	76
2-4. Summary of Studies of Associations between DDT Exposure Biometrics and Hematological Endpoints .....	81
2-5. Summary of Studies of Associations between DDT Exposure Biometrics and Musculoskeletal Endpoints .....	84
2-6. Summary of Studies of Associations between DDT Exposure Biometrics and Hepatic Endpoints .....	86
2-7. Summary of Studies of Associations Between DDT Exposure Biometrics in Adolescents or Adults and Serum Thyroid Hormone Levels.....	95
2-8. Summary of Studies of Associations Between Maternal Serum, Cord Blood, or Milk DDT Exposure Metrics and Thyroid-Related Outcomes in Offspring .....	101
2-9. Summary of Studies of Associations Between DDT Exposure Biometrics in Adults and Immunological Endpoints.....	108
2-10. Summary of Studies of Associations between DDT Exposure Biometrics in Children and Immunological Endpoints .....	110
2-11. Summary of Studies of Associations Between Maternal Serum, Cord Blood, or Milk DDT Exposure Metrics and Immunological Endpoints in Offspring .....	113
2-12. Summary of Neurological Perturbations in Adult or Adolescent Humans with DDT Exposure Biometrics.....	126
2-13. Summary of Studies of Associations between Maternal Serum, Cord Blood, Breast Milk, or Placental DDT Exposure Biometrics and Neurological Outcomes in Offspring .....	130
2-14. Summary of Reproductive Outcomes in Adult Humans with DDT Exposure Biometrics .....	151
2-15. Summary of Studies of Associations between Human DDT Exposure Metrics in Child and Adolescent Serum and Reproductive Endpoints .....	167
2-16. Summary of Studies of Associations between Human DDT Exposure Metrics in Maternal Serum, Cord Blood, or Breast Milk and Reproductive Endpoints in Offspring Biometrics .....	169

2-17. Number of Studies Finding Statistically Significant Associations and No Significant Associations Between Serum Levels of DDT, DDD, or DDE and Levels of Sex Hormones in Serum or Urine .....	177
2-18. Summary of Studies of Associations Between Human Maternal DDT Exposure Metrics and Offspring Weight and Growth Endpoints at Birth.....	188
2-19. Summary of Studies of Associations between Human Maternal DDT Exposure Metrics and Post-Birth Offspring Body Weight and Growth.....	197
2-20. Summary of Diabetes Outcomes in Humans with DDT Exposure Biometrics .....	211
2-21. Genotoxicity of DDT, DDE, and DDD <i>In Vivo</i> .....	232
2-22. Genotoxicity of DDT, DDE, and DDD <i>In Vitro</i> .....	239
3-1. Tissue:Blood Partition Coefficients and Pharmacokinetic Constants for Modeling DDE Disposition in the Pregnant Rat .....	254
3-2. Physiological Constants Used in the PBPK Model for the Lactating Dam and the Nursing Pup ....	254
4-1. Chemical Identity of <i>p,p'</i> - and <i>o,p'</i> -DDT, DDE, and DDD .....	266
4-2. Physical and Chemical Properties of <i>p,p'</i> - and <i>o,p'</i> -DDT, DDE, and DDD .....	268
5-1. Lowest Limit of Detection Based on Standards .....	288
5-2. Summary of Environmental Levels of DDT, DDE, and DDD.....	288
5-3. DDT, DDE, and DDD Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	289
5-4. DDD, DDE, and DDT Levels in Sediment Obtained from the Upper Steele Bayou Watershed .....	295
5-5. Concentrations of DDT and Metabolites in Biota .....	303
5-6. Average Residues in Food Groups and Average Daily Intake from U.S. Food and Drug Administration (FDA) Total Diet Studies .....	307
5-7. Results of the FDA Market Basket Surveys from 2003 to 2005 for DDT, DDE, and DDD.....	308
5-8. DDD, DDE, and DDT Residues in Food Items Sampled in 2014.....	312
5-9. Mean Daily Intake of DDT Per Unit Body Weight ( $\mu\text{g}/\text{kg}$ body weight/day) for Various Age Groups in the United States .....	319
5-10. Geometric Mean and Selected Percentiles of Serum <i>p,p'</i> -DDT (Lipid Adjusted in ng/g of Lipid or ppb on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.....	323

5-11. Geometric Mean and Selected Percentiles of Serum <i>p,p'</i> -DDT (Whole Weight Lipid in ng/g of Serum or ppb) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.....	324
5-12. Geometric Mean and Selected Percentiles of <i>p,p'</i> -DDE (Lipid Adjusted in ng/g of Lipid or ppb on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.....	326
5-13. Geometric Mean and Selected Percentiles of <i>p,p'</i> -DDE (Whole Weight in ng/g of Serum or ppb) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.....	327
5-14. Levels of DDT Compounds in Human Milk, Blood, and Tissues.....	331
6-1. Ongoing Studies on DDT, DDE, and DDD.....	352
7-1. Regulations and Guidelines Applicable to DDT, DDE, and DDD.....	353